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ABSTRACT 
 
Important and novel roles for neuropeptide Y (NPY) signaling in the control of bone homeostasis have 
recently been identified, with deletion of either the Y1 or Y2 receptors resulting in a generalized 
increase in bone formation. Whereas the Y2 receptor-mediated anabolic response is mediated by a 
hypothalamic relay, the Y1-mediated response is likely mediated by osteoblastic Y1 receptors. The 
presence of Y1 receptors on osteoblasts and various other peripheral tissues suggests that, in addition 
to neuronal input, circulating factors may also interact with the Y1-mediated pathways. The skeletal 
and adipose tissue (peripheral and marrow) responses to Y1 receptor deficiency were examined after 
(1) leptin deficiency, (2) gonadectomy, and (3) hypothalamic NPY overexpression. Bone formation was 
consistently increased in intact Y1−/− mice. However, the hypogonadism of gonadectomy or leptin 
deficiency blocked this anabolism in male Y1−/− mice, whereas females remained unchanged. The 
Y1-mediated bone anabolic pathway thus seems to be dependent on the presence of intact androgen 
signaling. Y1 deficiency also led to increased body weight and/or adiposity in all experimental models, 
with the exception of male ob/ob, showing a general adipogenic effect of Y1 deficiency that is not 
dependent on androgens. Interestingly, marrow adipocytes were regulated differently than general 
adipose depots in these models. Taken together, this interaction represents a novel mechanism for the 
integration of endocrine and neural signals initiated in the hypothalamus and provides further insight 
into the coordination of bone and energy homeostasis. 
 
INTRODUCTION 
 
The hypothalamus is a dominant modulator of endocrine functions by its actions on the pituitary. The 
hormonal products of this axis exert powerful regulatory influences throughout the body. More recently, 
the role of nonhormonal outputs from the hypothalamus has generated increasing interest in light of 
evidence of links from this region of the brain to peripheral tissues and the critical role direct neural 
signaling plays in peripheral tissue homeostasis. One such neural pathway is the neuropeptide Y 
(NPY) system. This system is made up of three ligands, NPY, peptide YY, and pancreatic polypeptide, 
and mediates its effects through five Y-receptors (Y1, Y2, Y4 Y5, and Y6). Whereas the NPY system 
has predominantly been recognized for its potent effects on energy homeostasis and food intake, it is 
now known that this system influences many physiological processes including behavior, immunity, 
and the cardiovascular system. The musculoskeletal effects of NPY have gained particular attention, 
because of the ability of Y2 receptors within the hypothalamus to strongly regulate the formation of 
bone, in part through alterations of sympathetic nervous output1. In addition to this central action of Y2 
receptors, Y1 receptors expressed on the osteoblast have also been implicated in this process 
suggesting direct, local actions in these cells2. Examination of Y1-deficient mice showed greater bone 
mass and formation but also marked changes in adipose tissue homeostasis3. The Y1 receptor 
therefore seems to represent a critical site for integration of this centrally mediated neural pathway and 
its peripheral target cells. 
 Interestingly, the peripheral expression pattern and the action of Y1 receptor in the regulation 
of bone and adipose tissue suggest an increased potential for interaction of the Y1 receptor system 
with other peripherally acting regulatory pathways. Thus, Y1 receptor signaling may also represent a 
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mechanism through which endocrine and neural hypothalamic circuits converge to modulate peripheral 
homeostatic processes. To study this possibility, the interaction of Y1 with a number of known 
regulators of bone and adipose tissue including leptin, sex steroids, and NPY was examined. The 
adipocyte hormone leptin is a powerful modulator of bone and adipose homeostasis. In addition to 
profound obesity, leptin-deficient mice (ob/ob),4,5 have altered bone homeostasis, with decreased 
cortical production6 and increased cancellous bone formation and osteoclast activity.7 Sex steroids 
have a well-defined role in both bone and adipose homeostasis with reduced levels of sex hormones 
resulting in increased bone resorption,8,9 and fat accrual10,11., Moreover, in addition to its role in feeding 
behavior and adipose deposition, central NPY overexpression has also been shown to inhibit bone 
formation12. 
 The mode of any interaction of these regulators of bone and adipose with Y1 signaling is 
unknown; hence, potential interactions were examined in in vivo models. Leptin-mediated effects were 
studied in Y1−/− mice crossed onto the leptin-deficient background, producing Y1−/−;ob/ob double 
knockout mice. The influence of sex hormone signaling was further examined by gonadectomy in 
germline Y1−/− mice. The effects of NPY overexpression, again a model for control of bone and 
adipose deposition was studied after injection of recombinant NPY-expressing adeno-associated viral 
vector into the hypothalamus of adult Y1−/− mice. Mice were assessed for changes in both skeletal 
and adipose homeostasis. 
 
MATERIALS AND METHODS 
 
Animal experiments were approved by the Garvan Institute of Medical Research Animal Research 
Authority and were conducted in accordance with relevant guidelines and regulations. 
 
Generation of knockout mice models 
 Germline deletion of the Y1 receptor gene was achieved as previously described.13 Briefly, 
Y1−/−;ob/ob mice were generated by crossing male and female heterozygous (ob/ob) mice on a mixed 
C57/BL6–129/SvJ background with Y1−/− mice on the same mixed background. Double heterozygous 
Y1+/−;Ob/ob mice were crossed again to obtain Y1−/−;ob/ob homozygous double knockout mice. All 
single and double knockout mice were maintained on this mixed C57/BL6–129/SvJ background. 
 
Surgical gonadectomy 
 Gonadectomy or sham operation was performed on germline Y1−/− male and female mice at 8 
wk of age, as previously described.14 Tissues were collected 8 wk after gonadectomy. 
 
Vector-mediated overexpression of NPY in the hypothalamus 
 Recombinant adeno-associated viral vector expressing NPY under the control of the neural 
specific enolase promoter (rAAV-NPY) was injected into the hypothalamus of 15-wk-old wildtype and 
Y1−/− mice using a stereotaxic table as previously described.12 Brain coordinates relative to bregma 
were posterior 2.1 mm, lateral ± 0.4 mm, and ventral 5.3 mm. One microliter of vector (1 × 1012 
genome copies/ml) was injected bilaterally over 5 min using a 26-gauge guide cannula and a 33-gauge 
injector (Plastics One, Roanoke, VA, USA) connected to a Hamilton Syringe and a syringe infusion 
pump (World Precision Instruments, Waltham, MA, USA). Control groups were injected with GFP 
expressing vector (AAV-GFP). The efficacy of vector injection was assessed as previously described.12 
 
Tissue collection 
 Mice were injected with 15 mg/kg of the fluorophore calcein (Sigma Chemical Co., St Louis, 
MO, USA) 10 and 3 days before tissue collection to enable subsequent calculation of bone formation 
rate. Gonadectomized and sham-operated mice, as well as Y1−/−;ob/ob mice were culled at 16 wk of 
age, AAV-injected mice were collected at 18 wk of age, 3 wk after viral injection. Mice were killed, and 
the brain was removed and immediately frozen on dry ice. White adipose tissue (WAT) depots (right 
inguinal, right retroperitoneal, reproductive [right ovarian or right epididymal for female and male mice, 
respectively], and mesenteric) were collected and weighed. Both femora were excised and fixed in 4% 
paraformaldehyde for 16 h. 
 
Bone histomorphometry 
 The right femur was bisected transversely at the midpoint of the shaft. Distal halves were 
embedded, undecalcified in methyl-methacrylate (Medim-Medizinische Diagnostik, Giessen, 
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Germany), and 5-μm sagittal sections were analyzed as previously described.  Sections were 
stained for mineralized bone, cancellous bone volume (BV/TV), trabecular number (Tb.N), trabecular 
thickness (Tb.Th) were calculated. Bone formation indices (mineralizing surface [MS], mineral 
apposition rate [MAR], bone formation rate [BFR]), and osteoclast surface (Oc.S) were calculated as 
previously described,1 using Leica QWin analysis software (Leica Microsystems, Heerberg, 
Switzerland). To avoid possible adverse interaction of the tetracycline-based calcein labels with AAV 
activity, mice receiving AAV virus did not receive calcein injections; thus, it was not possible to 
calculate parameters of osteoblast activity as done in the other samples. Instead, osteoid parameters 
were measured on Masson's trichrome-stained sections as previously described.12 Marrow adiposity 
was assessed using H&E-stained sections, based on the identification of circular voids in the bone 
marrow made by adipocytes that had been removed during processing. These were distinguished from 
sinusoids and blood vessels by lack of H&E staining. Adipocyte number and area were calculated 
using Leica QWin analysis software and expressed as total adipocyte volume as a percentage of total 
marrow volume. 
 
Statistical analysis 
 All data are expressed as mean ± SE. Differences between multiple groups were assessed by 
factorial ANOVA, followed by Fisher's posthoc comparisons, using StatView version 4.5 (Abacus 
Concepts, San Francisco, CA, USA). For all statistical analyses, p < 0.05 was accepted as being 
statistically significant. 
 
RESULTS 
 
Sex-specific involvement of leptin in the anabolic effects of Y1 receptor deficiency in cancellous bone 
 To evaluate the potential for Y1 receptors to interact with other mediators of bone and adipose 
homeostasis, the effects of Y1 signaling in the leptin-deficient, hypogonadal ob/ob mice were 
examined by comparing the bone phenotypes of Y1−/− mice to those of ob/ob and Y1−/−;ob/ob double 
mutant mice. 
 Lack of Y1 receptors in Y1−/− mice or lack of leptin in ob/ob animals each resulted in marked13 
and significant increases in cancellous bone volume and trabecular number and thickness compared 
with wildtype mice, with the exception of Tb.N in male ob/ob mice. These increases occurred despite 
significantly greater surface extent of osteoclasts in male Y1−/− or ob/ob mice and in female ob/ob 
mice. Bone formation, however, was increased in both genotypes and sexes, with significantly greater 
mineral apposition rate compared with wild types (Fig. 1), consistent with previous characterizations of 
the Y1−/− and ob/ob models3,6.	  
 Study of Y1−/−;ob/ob double mutant mice showed a lack of additive action of Y1 and leptin 
deficiency in the control of both the osteoblast and osteoclast lineages in bone (Fig. 1), as has been 
described previously for Y2 and leptin6. Moreover, in male Y1−/−;ob/ob mice, not only were there no 
additive effects of Y1 and leptin deficiency on bone physiology, but the anabolic effects of Y1 or leptin 
deficiency were absent. This included abolition of the increases in cancellous bone volume and mineral 
apposition rate evident in Y1−/− and ob/ob mice (Fig. 1). This effect appeared cell specific, with the 
greater osteoclast surface of leptin deficiency still evident in male Y1−/−;ob/ob. In contrast, in females, 
the effects of Y1 or leptin deficiency to increase trabecular bone volume and mineral apposition rate 
were retained in Y1−/−;ob/ob mice (Fig. 1). These findings suggest that, in males, the effects of Y1 
deficiency to induce anabolic effects on cancellous bone volume and mineral apposition rate require 
leptin or a downstream effect of leptin's actions to manifest. 
	  
Leptin-deficient obesity syndrome of ob/ob mice is modulated by Y1 signaling 
 In addition to its effects on bone physiology, Y1 receptor deficiency also has significant effects 
on energy homeostasis3. We therefore examined whether Y1 receptor knockout influences the obesity 
syndrome of genetically obese mice. 
Y1 deletion alone resulted in an obesity syndrome in both sexes that is particularly apparent in 
female Y1−/− mice, with increased body weight and a generalized increase in white adipose tissue 
depots compared with wildtype (Fig. 2). Conversely, when bred onto the obese ob/ob background, Y1 
deletion resulted in a significant decrease in body weight in Y1−/−;ob/ob mice of both sexes (Fig. 2). In 
male Y1−/−;ob/ob mice, this decrease was associated with reduced reproductive (epididymal) WAT 
mass, with a smaller contribution by the inguinal depot. In females, however, despite the decrease in 
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weight in Y1−/−;ob/ob, adipose mass was increased, again because of a change in reproductive 
(ovarian) depot mass and a smaller contribution by the retroperitoneal depot. 
	  
	  	  
Leptin-deficient ob/ob mice are characterized by hormonal and metabolic changes including 
elevated glucose, insulin, and corticosterone and reduced IGF-1 (Table 1). Additionally, the small 
intestine and liver of male and female ob/ob mice are markedly hypertrophied (Table 1). Crossing 
Y1−/− mice onto the ob/ob background rescued or partially rescued several of these features. Serum 
glucose and corticosterone as well as the weight and length of the small intestine were significantly 
reduced from ob/ob values and/or were not different from wildtype values in Y1−/−;ob/ob mice. 
Interestingly, there were several sex-specific effects. Liver weight was reduced in female Y1−/−;ob/ob 
mice only, consistent with their decrease in body weight despite greater adiposity. Whereas Y1 
receptor knockout partially rescued the hyperinsulinemia of male ob/ob mice, female Y1−/−;ob/ob mice 
had serum insulin levels that were at least as high as female ob/ob mice (Table 1). 
Y1 knockout increased the mass of WAT depots in males and females (Fig. 2), but in male 
mice, no adipogenic effect of Y1 receptor deficiency was seen in the number, size, or total volume of 
adipocytes within the bone marrow (Fig. 3), consistent with differential regulation of WAT depots and 
marrow adipocytes. In female Y1−/− mice, however, there was a trend to increases in marrow 
adipocyte volume and number, albeit this difference did not reach statistical significance when 
analyzed in conjunction with ob/ob mice (Figs. 3A and 3B). In contrast, ob/ob mice displayed markedly 
greater adiposity in bone marrow compared with all genotypes (Fig. 3). In Y1−/−;ob/ob mice, marrow 
adipocyte number and total marrow adipocyte volume were significantly reduced compared with ob/ob, 
suggesting that the increased adiposity seen in the bone marrow microenvironment of ob/ob mice of 
both sexes is mediated at least in part by Y1 receptor signaling. 
         Interestingly, the infertility of ob/ob is not dependent on Y1 receptor signaling. None of five 
breeding pairs consisting of either male or female Y1−/−;ob/ob mice mated with corresponding 
wildtype mice produced any offspring after a 12-wk period. Moreover, inhibition of the hypothalamo-
pituitary gonadotropic axis seen in ob/ob mice was not rescued by Y1 receptor deficiency in our hands, 
because both ob/ob and Y1−/−;ob/ob mice showed significant reductions in testis and seminal vesicle 
weight and marked (albeit nonsignificant) reductions in serum testosterone levels compared with 
wildtype values (Table 1). This contrasts with another study, in which Y1 receptor knockout normalized 
the low pituitary leuteinizing hormone content and seminal vesicle weights of male ob/ob mice.15 
 
For all statistical analyses, p < 0.05 was accepted as being
statistically significant.
RESULTS
Sex-specific involvement of leptin in the anabolic
effects of Y1 receptor deficiency in cancellous bone
To evaluate the po ential for Y1 rec ptors to interact
with other mediators of bone and adipose homeostasis, the
effects of Y1 signaling in the leptin-deficient, hypogonadal
ob/ob mice were examined by comparing the bone phe-
notypes of Y12/2 mice to those of ob/ob and Y12/2;ob/ob
double mutant mice.
Lack of Y1 receptors inY12/2mice or lack of leptin in ob/
ob animals each result d in marked and significant increases
in cance lous bo e volum and trabecular number and
thickness compared with wildtype mice, with the exception
of Tb.N in male ob/ob mice. These increases occurred de-
spite significantly greater surface extent of osteoclasts in
male Y12/2 or ob/ob mice and in female ob/ob mice. Bone
formation, however, was increased in both genotypes and
sexes, with significantly greater mineral apposition rate
compared with wild typ s (Fig. 1), consistent with previous
characte izati of the Y12/2 and ob/ob models.(3,6)
Study of Y12/2;ob/ob double mutant mice showed a lack
of additive action of Y1 and leptin deficiency in the control
of both the osteoblast and osteoclast lineages in bone (Fig. 1),
as has been described previously for Y2 and leptin.(6)
Moreover, in male Y12/2;ob/ob mice, not only were there
no additive effects of Y1 and leptin deficiency on bone
physiology, but the anabolic effects of Y1 or leptin defi-
ciency were absent. This included abolition of the increases
in cancellous bone volume and mineral apposition rate
evident in Y12/2 and ob/ob mice (Fig. 1). This effect ap-
peared cell specific, with the greater osteoclast surface of
leptin deficiency still evident in male Y12/2;ob/ob. In
contrast, in females, the effects of Y1 or leptin deficiency to
increase trabecular bone volume and mineral apposition
rate were retained in Y12/2;ob/ob mice (Fig. 1). These
findings suggest that, in males, the effects of Y1 deficiency
to induce anabolic effects on cancellous bone volume and
mineral apposition rate require leptin or a downstream
effect of leptin’s actions to manifest.
Leptin-deficient obesity syndrome of ob/ob mice is
modulated by Y1 signaling
In addition to i s effects on bo e physiology, Y1 receptor
deficiency also has significant effects on energy homeosta-
sis.(3) We therefore examined whether Y1 receptor knockout
influences the obesity syndrome of genetically obese mice.
Y1 deletion alone resulted in an obesity syndrome in
both sexes that is particularly apparent in female Y12/2
mice, with increased body weight and a generalized in-
crease in white adipose tissue depots compared with
wildtype (Fig. 2). Conversely, when bred onto the obese
ob/ob background, Y1 deletion resulted in a significant
decrease in body weight in Y12/2;ob/ob mice of both sexes
(Fig. 2). In male Y12/2;ob/ob mice, this decrease was as-
sociated with reduced reproductive (epididymal) WAT
mass, with a smaller contribution by the inguinal depot. In
females, however, despite the decrease in weight in Y12/2;
FIG. 1. Effect of Y1 receptor deletion on trabecular bone morphology and bone cell activity of ob/ob mice. Female (A–E), and male
(F–J) mice. Cancellous bone volume (A and F), trabecular number (B and G), trabecular thickness (C and H), osteoclast surface (D and I),
and mineral apposition rate (E and J). *p < 0.05 vs. wildtype; #p < 0.05 as indicated. n = 7–10 per genotype.
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    ob/ob, adipose mass was increased, again because of a
change in reproductive (ovarian) depot mass and a smaller
contribution by the retroperitoneal depot.
Leptin-deficient ob/ob mice are characterized by hor-
monal and metabolic changes including elevated glucose,
insulin, and corticosterone and reduced IGF-1 (Table 1).
Additionally, the small intestine and liver of male and fe-
male ob/ob mice are markedly hypertrophied (Table 1).
Crossing Y12/2 mice onto the ob/ob background rescued
or partially rescued several of these features. Serum glu-
cose and corticosterone as well as the weight and length of
the small intestine were significantly reduced from ob/ob
values and/or were not different from wildtype values in
Y12/2;ob/obmice. Interestingly, therewere several sex-specific
effects. Liver weight was reduced in female Y12/2;ob/ob
mice only, consistent with their decrease in body weight
despite greater adiposity. Whereas Y1 receptor knockout
partially rescued the hyperinsulinemia of male ob/obmice,
female Y12/2;ob/ob mice had serum insulin levels that
were at least as high as female ob/ob mice (Table 1).
Y1 knockout increased the mass of WAT depots in
males and females (Fig. 2), but in male mice, no adipogenic
effect of Y1 receptor deficiency was seen in the number,
size, or total volume of adipocytes within the bone
marrow (Fig. 3), consistent with differential regulation of
WAT depots and marrow adipocytes. In female Y12/2
mice, however, there was a trend to increases in marrow
adipocyte volume and number, albeit this difference
FIG. 2. Effect of Y1 receptor knockout on body weight and adiposity in lean and genetically obese (ob/ob) mice. Female (A–F), and
male (G–L) mice. Body weight (A and G), total excised white adipose tissue (WAT) deposits (B and H), right inguinal (C and I), right
reproductive (periovarian, D) or (epididymal, J) mesenteric (E and K), and right retroperitoneal (F and L) from 15- to 16-wk-old
wildtype (WT), Y1 receptor knockout (Y12/2), ob/ob, or Y1 ob double mutant (Y12/2;ob/ob) mice were weighed and expressed as a
percent of body weight. Data are means ± SE of seven or more female or six or more male mice per group. *p < 0.05 vs. WT mice; # p <
0.05 as indicated. n = 12–16 per genotype.
TABLE 1. EFFECT OF Y1 RECEPTOR KNOCKOUT ON CIRCULATING GLUCOSE AND HORMONE LEVELS IN LEAN
AND GENETICALLY OBESE (OB/OB) MICE
Female Male
WT Y12/2 ob/ob Y12/2ob WT Y12/2 ob/ob Y12/2ob
Glucose (mM) 10.1 ± 0.3 9.8 ± 0.3 16.7 ± 2.6* 10.8 ± 0.5† 9.3 ± 0.2 10.3 ± 0.3 19.5 ± 2.7* 13.4 ± 1.9†
Insulin (pM) 70 ± 10 200 ± 30 1860 ± 580* 2400 ± 1300* 130 ± 10 270 ± 80 5400 ± 1790* 2050 ± 1900
Cortico (ng/ml) 155 ± 16 121 ± 20 202 ± 37 228 ± 52 73 ± 11 79 ± 28 406 ± 109* 205 ± 67†
IGF-1 (ng/ml) 289 ± 17 343 ± 22 203 ± 44‡ 304 ± 61 266 ± 26 245 ± 24 195 ± 34 190 ± 88
Intestine (g) 1.22 ± 0.07 1.21 ± 0.05 1.83 ± 0.11* 1.24 ± 0.09x 1.16 ± 0.06 1.11 ± 0.06 1.96 ± 0.07* 1.63 ± 0.25†{
Intestine (cm) 38.6 ± 1.0 34.0 ± 0.5{ 47.0 ± 1.4* 36.8 ± 1.7x 36.9 ± 2.3 36.3 ± 0.7 46.8 ± 1.5{ 42.9 ± 2.6
Liver (g) 1.05 ± 0.03 1.25 ± 0.03 3.99 ± 0.34* 2.58 ± 0.21*x 1.34 ± 0.03 1.34 ± 0.04 4.68 ± 0.03* 4.20 ± 0.43*
Testis (g) ND ND ND ND 0.117 ± 0.003 0.106 ± 0.003‡ 0.097 ± 0.007{ 0.096 ± 0.01{
Sem V (g) ND ND ND ND 0.13 ± 0.01 0.13 ± 0.01 0.09 ± 0.01{ 0.09 ± 0.02‡
Testost (nM) ND ND ND ND 8.6 ± 2.9 10.3 ± 2.9 3.0 ± 1.1 3.2 ± 1.8
Data are means ± SE of seven or more female or six or more male mice per group.
*p < 0.001, ‡p < 0.05, and {p < 0.01 vs. wildtype (WT) mice of the same sex.
†p < 0.05 and x0.001 vs. ob/ob mice of the same sex.
ND, not determined.
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Y1 receptor knockout protects against gonadectomy-induced bone loss in female but not male mice 
 To examine potential interactions between circulating sex steroids and Y1 action in bone, 
cancellous bone was examined in gonadectomized Y1−/− and wildtype mice. 
  The effects of Y1 receptor deficiency to increase cancellous bone volume, trabecular number 
and thickness, and mineral apposition rate observed in intact animals (Fig. 1) were also observed in 
sham-operated Y1−/− mice (Fig. 4). There was no change in mineralizing surface with Y1 receptor 
knockout. However, the resultant bone formation rate was significantly greater in female but not 
male sham-operated Y1−/− mice (Fig. 4). 
 
 
did not reach statistical significance when analyzed in
conjunction with ob/obmice (Figs. 3A and 3B). In contrast,
ob/ob mice displayed markedly greater adiposity in bone
marrow compared with all genotypes (Fig. 3). In Y12/2;ob/
ob mice, marrow adipocyte number and total marrow
adipocyte volume were significantly reduced compared
with ob/ob, suggesting that the increased adiposity seen
in the bone marrow microenvironment of ob/ob mice
of both sexes is mediated at least in part by Y1 receptor
signaling.
Interestingly, the infertility of ob/ob is not dependent on
Y1 receptor signaling. None of five breeding pairs consisting
of either male or female Y12/2;ob/ob mice mated with
corresponding wildtype mice produced any offspring after a
12-wk period. Moreover, inhibition of the hypothalamo-
pituitary gonadotropic axis seen in ob/ob mice was not res-
cued by Y1 receptor deficiency in our hands, because both
ob/ob and Y12/2;ob/ob mice showed significant reductions
in testis and seminal vesicle weight and marked (albeit
nonsignificant) reductions in serum testosterone levels
compared with wildtype values (Table 1). This contrasts
with another study, in which Y1 receptor knockout nor-
malized the low pituitary leuteinizing hormone content and
seminal vesicle weights of male ob/ob mice.(15)
Y1 receptor knockout protects against
gonadectomy-induced bone loss in female
but not male mice
To examine potential interactions between circulating
sex steroids and Y1 action in bone, cancellous bone was
examined in gonadectomized Y12/2 and wildtype mice.
The effects of Y1 receptor deficiency to increase can-
cellous bone volume, trabecular number and thickness, and
mineral apposition rate observed in intact animals (Fig. 1)
were also observed in sham-operated Y12/2 mice (Fig. 4).
There was no change in mineralizing surface with Y1 re-
ceptor knockout. However, the resultant bone formation
rate was significantly greater in female but not male sham-
operated Y12/2 mice (Fig. 4).
In wildtype mice, gonadectomy halved cancellous bone
volume in association with the loss of trabecular number
and increase in osteoclast surface (Fig. 4). Despite the in-
crease in bone resorption, no change in mineralizing sur-
face, mineral apposition rate, or bone formation rate was
evident postgonadectomy. In Y12/2 mice, gonadectomy-
induced bone loss was evident in both sexes, with loss of
both cancellous bone volume and trabecular number, but
the extent of bone loss varied between males and females.
In female mice, cancellous bone volume was reduced by
a similar proportion in both genotypes (wildtype, 48%;
Y12/2, 41%), and cancellous bone volume and trabecular
number and thickness remained significantly greater in
ovariectomized Y12/2mice compared with ovariectomized
wildtype mice (Fig. 4), similar to previously described ef-
fects of ovariectomy in Y22/2 mice.(14) This maintenance
of greater cancellous bone volume in ovariectomized Y12/2
mice was associated with a nonsignificant increase in oste-
oclast surface and a consistently greater mineral apposition
rate and bone formation rate (Fig. 4). These data indicate
that loss of Y1 receptor signaling partially protects against
ovariectomy-induced osteopenia in female mice.
In male mice, however, Y1 deletion did not protect
against orchidectomy-induced osteopenia. The signifi-
cantly greater cancellous bone volume, trabecular number,
and mineral apposition rate of sham-operated Y12/2 mice
were abolished by orchidectomy (Fig. 4). Loss of cancel-
lous bone volume was more extensive in Y12/2 compared
with wildtype (wildtype, 50%; Y12/2, 69%). The elevation
in osteoclast surface was no different between Y12/2 and
wildtype mice after orchidectomy (Fig. 4). In the absence
of differing resorption, the decrease in mineral apposition
FIG. 3. Effect of Y1 receptor deletion on
marrow adiposity of ob/ob mice. Female
(A–C) and male (D–F) mice. Marrow adi-
pocyte number (A and D), average adipocyte
size (B and E), and marrow adipocyte vol-
ume (C and F). *p < 0.05 vs. wildtype; #p <
0.05 as indicated. n = 7–10 per genotype.
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rate in hypogonadal male Y12/2 seems critical to the ex-
aggerated bone loss after orchidectomy.
Y1 receptor deletion increases weight gain and fat
accumulation after gonadectomy
Sham-operated Y12/2 mice exhibited increases in body
weight and WAT mass compared with sham-operated
wildtype mice, and this effect was most evident in females
(Fig. 5). In wildtype mice, gonadectomy led to sex-specific
effects on body weight and WAT mass. Whereas female
mice showed ovariectomy-induced increases in body weight
and fat mass, male mice showed decreases in body weight
and adiposity after orchidectomy (Fig. 5).
Y1 receptor deficiency, however, led to significant
gonadectomy-induced increases in body weight and/or
WAT mass over and above values seen in gonadectomized
wildtype or intact Y1 knockout animals in specific sites,
namely the inguinal and mesenteric WAT depots (Fig.
5). This was the same in both male and female mice. In-
terestingly, unlike female Y12/2 mice in which ovariec-
tomy significantly increased body weight, no such increase
in body weight was seen in male Y12/2 orchidectomized
mice.
FIG. 4. Effect of gonadectomy (ovariectomy [OVX] or orchidectomy [ORX]) and germline Y1 receptor deletion on cancellous bone of
female (A–G) and male (H–N) mice. Cancellous bone volume (A and H), trabecular number (B and I), trabecular thickness (C and J),
o teoclast surface (D and K), mineralizing surf ce (E and L), miner l apposition rate (F andM), and bone formation rate (G and N). *p <
0.05 vs. wildtype within equivalent operation; #p < 0.05 vs. sham within the same genotype. n = 8–13 per operation/genotype.
FIG. 5. Effect of gonadectomy and germline Y1 receptor deletion on body composition of female (A–E) and male (F–J) mice. Body
weight (A and F), total WAT (B and G) inguinal (C and H), mesenteric (D and I), and retroperitoneal (E and J) mass. *p < 0.05 vs.
wildtype within equivalent operation; #p < 0.05 vs. sham within the same genotype. n = 8–13 per operation/genotype.
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 In wildtype mice, gonadectomy halved cancellous bone volume in association with the loss of 
trabecular number and increase in osteoclast surface (Fig. 4). Despite the increase in bone 
resorption, no change in mineralizing surface, mineral apposition rate, or bone formation rate was 
evident postgonadectomy. In Y1−/− mice, gonadectomy-induced bone loss was evident in both 
sexes, with loss of both cancellous bone volume and trabecular number, but the extent of bone loss 
varied between males and females. In female mice, cancellous bone volume was reduced by a 
similar proportion in both genotypes (wildtype, 48%; Y1−/−, 41%), and cancellous bone volume and 
trabecular number and thickness remained significantly greater in ovariectomized Y1−/− mice 
compared with ovariectomized wildtype mice (Fig. 4), similar to previously described effects of 
ovariectomy in Y2−/− mice.14 This maintenance of greater cancellous bone volume in 
ovariectomized Y1−/− mice was associated with a nonsignificant increase in osteoclast surface and 
a consistently greater mineral apposition rate and bone formation rate (Fig. 4). These data indicate 
that loss of Y1 receptor signaling partially protects against ovariectomy-induced osteopenia in 
female mice. 
 In male mice, however, Y1 deletion did not protect against orchidectomy-induced osteopenia. 
The significantly greater cancellous bone volume, trabecular number, and mineral apposition rate of 
sham-operated Y1−/− mice were abolished by orchidectomy (Fig. 4). Loss of cancellous bone 
volume was more extensive in Y1−/− compared with wildtype (wildtype, 50%; Y1−/−, 69%). The 
elevation in osteoclast surface was no different between Y1−/− and wildtype mice after 
orchidectomy (Fig. 4). In the absence of differing resorption, the decrease in mineral apposition rate 
in hypogonadal male Y1−/− seems critical to the exaggerated bone loss after orchidectomy. 
 
Y1 receptor deletion increases weight gain and fat accumulation after gonadectomy 
 Sham-operated Y1−/− mice exhibited increases in body weight and WAT mass compared with 
sham-operated wildtype mice, and this effect was most evident in females (Fig. 5). In wildtype mice, 
gonadectomy led to sex-specific effects on body weight and WAT mass. Whereas female mice 
showed ovariectomy-induced increases in body weight and fat mass, male mice showed decreases 
in body weight and adiposity after orchidectomy (Fig. 5). 
 Y1 receptor deficiency, however, led to significant gonadectomy-induced increases in body 
weight and/or WAT mass over and above values seen in gonadectomized wildtype or intact Y1 
knockout animals in specific sites, namely the inguinal and mesenteric WAT depots (Fig. 5). This 
was the same in both male and female mice. Interestingly, unlike female Y1−/− mice in which 
ovariectomy significantly increased body weight, no such increase in body weight was seen in male 
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WAT mass over and above values seen in gonadectomized
wildtype or intact Y1 knockout animals in specific sites,
namely the inguinal and mesenteric WAT depots (Fig.
5). This was the same in both male and female mice. In-
terestingly, unlike female Y12/2 mice in which ovariec-
tomy significantly increased body weight, no such increase
in body weight was seen in male Y12/2 orchidectomized
mice.
FIG. 4. Effect of gonadectomy (ovariectomy [OVX] or orchidectomy [ORX]) and germline Y1 receptor deletion on cancellous bone of
female (A–G) and male (H–N) mice. Cancellous bone volume (A and H), trabecular number (B and I), trabecular thickness (C and J),
osteoclast surface (D and K), mineralizing surface (E and L), mineral apposition rate (F andM), and bone formation rate (G and N). *p <
0.05 vs. wildtype within equivalent operation; #p < 0.05 vs. sham within the same genotype. n = 8–13 per operation/genotype.
FIG. 5. Effect of gonadectomy and germline Y1 receptor deletion on body composition of female (A–E) and male (F–J) mice. Body
weight (A and F), total WAT (B and G) inguinal (C and H), mesenteric (D and I), and retroperitoneal (E and J) mass. *p < 0.05 vs.
wildtype within equivalent operation; #p < 0.05 vs. sham within the same genotype. n = 8–13 per operation/genotype.
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Y1−/− orchidectomized mice. 
 In the marrow, intact Y1−/− mice showed a sex-specific difference in adiposity, with 
significantly greater volume and number of marrow adipocytes in females, and significant 
reductions in marrow adipocyte volume and number in males (Fig. 6). Consistent with effects in 
peripheral fat stores, marrow adipocyte volume was increased by gonadectomy in Y1−/− mice, with 
marked increases in adipocyte number (Fig. 6). This increase was most evident in males, despite a 
significantly lower adipocyte volume and number in sham-operated Y1−/− compared with sham-
operated wildtype mice. In wildtype mice, significant, albeit smaller, gonadectomy-induced 
increases in adipocyte volume and number were evident. Adipocyte size was not altered in any 
group. 
 
 
Lack of effect of Y1 receptor deletion on reduced bone formation induced by hypothalamic NPY 
overexpression 
 A critical factor to the changes evident in leptin-deficient mice is the increased expression of 
NPY in the hypothalamus, with many of the physiological effects in ob/ob mice attenuated in the 
absence of NPY.16 To study the influence of elevated hypothalamic NPY in the absence of Y1 receptor 
signaling, an adeno-associated viral vector expressing NPY was injected into the hypothalamus of 
wildtype and Y1−/− mice. 
        AAV-NPY-induced significant increases in body weight and adiposity in wildtype mice (Fig. 7). 
Y1−/− mice treated with AAV-NPY for 3 wk showed marked increases in body weight and adiposity 
over GFP vector-injected Y1−/− control mice, and these values were significantly greater than those 
seen in wildtype AAV-NPY-treated animals (Fig. 7). 
 
In the marrow, intact Y12/2 mice showed a sex-specific
difference in adiposity, with significantly greater volume
and number of marrow adipocytes in females, and signifi-
cant reductions in marrow adipocyte volume and number
in mal s (Fig. 6). Consistent with effects in p ripheral fat
stor s, marrow adipocyte volume was increased by go-
nadectomy in Y12/2 mice, with marked increases in adi-
pocyte number (Fig. 6). This increase was most evident in
males, despite a significantly lower adipocyte volume and
number in sham-operated Y12/2 compared with sham-
operated wildtype mice. In wildtype mice, significant, al-
beit smaller, gonadectomy-induced i c eases in adipocyt
volume and number were evident. Adipocyte size was not
altered in any group.
Lack of effect of Y1 receptor deletion on reduced
bone formation induced by hypothalamic
NPY overexpression
A critical factor to the changes evident in leptin-deficient
mice is the increased expression of NPY in the hypothal-
amus, with many of the physiological effects in ob/ob mice
attenuated in the absence of NPY.(16) To study the influ-
ence of elevated hypothalamic NPY in the absence of Y1
receptor signaling, an adeno-associated viral vector ex-
pressing NPY was injected into the hypothalamus of
wildtype and Y12/2 mice.
AAV-NPY–induced significant increases in body weight
and adiposity in wildtype mice (Fig. 7). Y12/2 mice treated
with AAV-NPY for 3 wk showed marked increases in body
weight and adiposity over GFP vector-injected Y12/2 con-
trol mice, and these values were significantly greater than
those seen in wildtype AAV-NPY–treated animals (Fig. 7).
Comparing wildtype and Y12/2 mice with hypothalamic
injection, cancellous bone volume was greater in AAV-
GFPY12/2mice comparedwithAAV-GFPwildtype (Fig. 7).
This difference was, however, abolished after hypothalamic
injection of AAV-NPY, with a reduction in cancellous bone
volume in Y12/2 mice. Cancellous bone volume of wildtype
mice was not reduced by AAV-NPY injection. However,
ost oblas activity, esti ated using osteoi wid , was mark-
edly reduced in both genotypes after AAV-NPY injection.
These data show that, despite a reduction in cancellous bone
volume, AAV-NPY–treated Y12/2 mice maintained their
elevated rate of osteoblast activity relative to wildtype levels.
Interestingly, marrow adipocyte volume did not respond
to central NPY administration, with the greater levels
in Y12/2 compared with wildtype mice unc ang d by
AAV-NPY injection, despite a decrease in adipocyte size
in Y12/2 AAV-NPY–injected mice.
DISCUSSION
These studies showed a key role for Y1 receptor sig-
naling in the regulation of bone and adipose homeostasis
and show critical interactions between this pathway and sex
steroids in the regulation of both tissues. In bone, the
presence of androgens was necessary for the anabolic ac-
tivity of the Y1-deficient pathway. In adipose tissue, lack of
Y1 signaling produced sex-specific changes in adiposity in
genetically obese ob/ob mice, and Y1 receptor deficiency
increased fat mass in both male and female gonadecto-
mized mice. Taken together, these data showed that Y1
receptors represent a novel site of interaction between
classic endocrine and neural pathways in the regulation of
both bone and adipose tissues.
The initial findings linking Y receptor signaling and bone
homeostasis were made in Y2 receptor-deficient models
and showed that hypothalamic Y2 receptors were re-
sponsible for tonic inhibition of osteoblast activity.(1) Im-
portantly, the recent identification of Y1 receptors on
osteoblastic cells may explain the generalized bone anabolic
FIG. 6. Effect of hypothalamic NPY over-
expression and germline Y1 receptor deletion
on body composition, cancellous bone, and
marrow adiposity of female mice. Female
(A–C), and male (D–F) mice. Marrow
adipocyte volume (A and D), marrow adi-
pocyte number (B and E), and mean adipo-
cyte size (C and F). *p < 0. 05 vs. Sham within
genotype; #p < 0.05 vs. WT within operation.
n = 8–13 per operation/genotype.
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response in germline but not hypothalamus-specific Y12/2
mice.(3) In addition, the effects of NPY on osteoblast-like
cultures were absent in Y12/2 cells, indicating a role for
direct control of anabolism by Y1 signaling. The NPY
pathway is known to interact with a number of humeral
factors such as leptin,(17) glucocorticoids,(18) and insulin.(19)
In such a manner, osteoblastic Y1 receptors may repre-
sent a point of integration between neural and humeral
signals.
Leptin deficiency is associated with numerous endocrine
changes including hypogonadism(4,5) and marked changes
in the regulation of both bone and adipose tissue.(5,7,12)
Interestingly, cancellous bone volume in Y12/2;ob/obmice
showed a sex-specific response compared with Y12/2 and
ob/ob mice. Whereas the elevated cancellous bone volume
seen in the single mutants was still evident in femaleY12/2;
ob/obmice, it was absent in males. This was consistent with
an attenuation of the anabolism ofY12/2 and ob/obmodels
rather than reductions in bone absorption. In contrast, the
anabolic response in female Y12/2;ob/ob mice remained
largely intact. Interestingly, Y1 deletion was unable to
rescue the hypogonadism of ob/ob mice, with both male
and female ob/ob and Y12/2;ob/ob mice remaining infer-
tile and male mice remaining hypogonadal, in contrast to
another report.(15) These findings implicate reduced tes-
tosterone levels in the inhibition of bone formation in this
model and therefore a potential requirement for andro-
genic steroids in Y1 signaling in bone.
Isolation of the hypogonadism of the ob/ob phenotype
using gonadectomy in otherwise intact Y12/2 mice con-
siderably simplified the endocrine aspects of the model and
showed a sex-specific response to the absence of gonadal
steroids in Y12/2 mice. Gonadectomy produced marked
bone loss in all groups, consistent with the known effects of
sex hormone deficiency in these models.(14) Importantly,
however, a marked reduction in osteoblast activity was
evident after the loss of gonadal steroids in male Y12/2 but
not females. This decrease was not reflected in mineralizing
surface, consistent with normal osteoblastogenesis, but
rather, a decrease in mineral apposition rate, suggesting a
reduction in osteoblast activity. Indeed, mineral apposition
rate of orchidectomized Y12/2 mice was not different to
wildtype and significantly reduced from intact Y12/2 mice.
In contrast to the response in males, loss of Y1 receptor
signaling in female mice provided some protection against
gonadectomy-induced bone loss in the distal femur, as
previously shown in both sexes of Y22/2 mice.(14)
It has been shown that an increase in hypothalamic NPY
levels, as in leptin-deficient mice or in mice with hypotha-
lamic administration of NPY, leads to decreased bone
mass.(6,12,20) As male Y1 receptor knockout mice have a
significant reduction in NPY mRNA expression in the ar-
cuate nucleus of the hypothalamus,(21) it is possible that a
reduction in central NPY-ergic signaling could contribute
to their anabolic bone phenotype. To test this possibility,
we used viral vector-mediated overexpression of NPY in
Y12/2 mice. Increased hypothalamic NPY, while capable
of reducing osteoblast activity in both wildtype and Y1
receptor knockout mice, did not abolish the greater oste-
oblast activity of the Y12/2 model. Thus, it seems that
other signals—possibly through androgens—and not solely
changes in central NPY-ergic activity are critical to the
anabolic activity associated with Y12/2 mice.
Appreciation of the skeletal effects of leptin has increased
the need for greater understanding of the regulation of adi-
pose tissue and its relationship to bone homeostasis. Y1
signaling, in addition to its effects in bone, also regulates
adipose tissue, with increased fat mass in both sexes ofY12/2
mice.(22) As in bone, this activity was not induced by deletion
of hypothalamic Y1 receptors, suggesting local regulation.(3)
The findings of reduced body weight in Y12/2;ob/ob mice
relative to ob/ob mice are in accordance with previous re-
ports for Y1(15) and other Y receptors.(17,23) However, there
were sex-specific differences in the influence of Y1 signaling
on fat, suggesting modulation of Y1 actions by endocrine
factors. In females, deletion of Y1 receptors increased WAT
mass in normal mice, as well as accentuated fat accrual in the
hypogonadal and leptin-deficient ob/obmodels. Of note, the
significantly greater fat mass but reduced body weight of
female Y12/2;ob/ob compared with ob/ob mice showed that
the weight reduction to be through loss of lean mass. This is
most likely because of change in organ weight, such as liver
and intestine rather than muscle mass, because IGF-1 levels
in female Y12/2;ob/ob are not reduced relative to wildtype
values as are female ob/ob levels.
In contrast to females, Y1 receptor deficiency in male ob/
obmice resulted in significant reductions in body weight and
adiposity. It is noteworthy that the significant hyperinsuli-
nemia of ob/ob mice was attenuated in male but not female
Y12/2;ob/obmice. Because insulin is lipogenic and promotes
FIG. 7. Effect of hypothalamic NPY overexpression and germline Y1 receptor deletio on body composition, cancellous bone, and
marrow adiposity of female mice. Final body weight (A), white adipos tissue (B), ca cellous bone volume (C), osteoid width (D),
marrow adipocyte volume (E), marrow adipocyte nu ber (F), and mean adipocyte size (G). *p < 0.05, vs. GFP within genotype; #p < 0.05
within treatment. n = 5–7 per injection/genotype.
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 Comparing wildtype and Y1−/− mice with hypothalamic injection, cancellous bone volume was 
greater in AAV-GFP Y1−/− mice compared with AAV-GFP wildtype (Fig. 7). This difference was, 
however, abolished after hypothalamic injection of AAV-NPY, with a reduction in cancellous bone 
volume in Y1−/− mice. Cancellous bone volume of wildtype mice was not reduced by AAV-NPY 
injection. However, osteoblast activity, estimated using osteoid width, was markedly reduced in both 
genotypes after AAV-NPY injection. These data show that, despite a reduction in cancellous bone 
volume, AAV-NPY-treated Y1−/− mice maintained their elevated rate of osteoblast activity relative to 
wildtype levels. 
 Interestingly, marrow adipocyte volume did not respond to central NPY administration, with the 
greater levels in Y1−/− compared with wildtype mice unchanged by AAV-NPY injection, despite a 
decrease in adipocyte size in Y1−/− AAV-NPY-injected mice. 
 
DISCUSSION 
 
These studies showed a key role for Y1 receptor signaling in the regulation of bone and adipose 
homeostasis and show critical interactions between this pathway and sex steroids in the regulation of 
both tissues. In bone, the presence of androgens was necessary for the anabolic activity of the Y1-
deficient pathway. In adipose tissue, lack of Y1 signaling produced sex-specific changes in adiposity in 
genetically obese ob/ob mice, and Y1 receptor deficiency increased fat mass in both male and female 
gonadectomized mice. Taken together, these data showed that Y1 receptors represent a novel site of 
interaction between classic endocrine and neural pathways in the regulation of both bone and adipose 
tissues. 
 The initial findings linking Y receptor signaling and bone homeostasis were made in Y2 
receptor-deficient models and showed that hypothalamic Y2 receptors were responsible for tonic 
inhibition of osteoblast activity.1 Importantly, the recent identification of Y1 receptors on osteoblastic 
cells may explain the generalized bone anabolic response in germline but not hypothalamus-specific 
Y1−/− mice.3 In addition, the effects of NPY on osteoblast-like cultures were absent in Y1−/− cells, 
indicating a role for direct control of anabolism by Y1 signaling. The NPY pathway is known to interact 
with a number of humeral factors such as leptin,17 glucocorticoids,18 and insulin.19 In such a manner, 
osteoblastic Y1 receptors may represent a point of integration between neural and humeral signals. 
 Leptin deficiency is associated with numerous endocrine changes including hypogonadism4,5 
and marked changes in the regulation of both bone and adipose tissue.5,7,12 Interestingly, cancellous 
bone volume in Y1−/−;ob/ob mice showed a sex-specific response compared with Y1−/− and ob/ob 
mice. Whereas the elevated cancellous bone volume seen in the single mutants was still evident in 
female Y1−/−;ob/ob mice, it was absent in males. This was consistent with an attenuation of the 
anabolism of Y1−/− and ob/ob models rather than reductions in bone absorption. In contrast, the 
anabolic response in female Y1−/−;ob/ob mice remained largely intact. Interestingly, Y1 deletion was 
unable to rescue the hypogonadism of ob/ob mice, with both male and female ob/ob and Y1−/−;ob/ob 
mice remaining infertile and male mice remaining hypogonadal, in contrast to another report.15 These 
findings implicate reduced testosterone levels in the inhibition of bone formation in this model and 
therefore a potential requirement for androgenic steroids in Y1 signaling in bone. 
 Isolation of the hypogonadism of the ob/ob phenotype using gonadectomy in otherwise intact 
Y1−/− mice considerably simplified the endocrine aspects of the model and showed a sex-specific 
response to the absence of gonadal steroids in Y1−/− mice. Gonadectomy produced marked bone loss 
in all groups, consistent with the known effects of sex hormone deficiency in these models.14 
Importantly, however, a marked reduction in osteoblast activity was evident after the loss of gonadal 
steroids in male Y1−/− but not females. This decrease was not reflected in mineralizing surface, 
consistent with normal osteoblastogenesis, but rather, a decrease in mineral apposition rate, 
suggesting a reduction in osteoblast activity. Indeed, mineral apposition rate of orchidectomized Y1−/− 
mice was not different to wildtype and significantly reduced from intact Y1−/− mice. In contrast to the 
response in males, loss of Y1 receptor signaling in female mice provided some protection against 
gonadectomy-induced bone loss in the distal femur, as previously shown in both sexes of Y2−/− 
mice.14 
 It has been shown that an increase in hypothalamic NPY levels, as in leptin-deficient mice or in 
mice with hypothalamic administration of NPY, leads to decreased bone mass.6,12,20 As male Y1 
receptor knockout mice have a significant reduction in NPY mRNA expression in the arcuate nucleus 
of the hypothalamus,21 it is possible that a reduction in central NPY-ergic signaling could contribute to 
their anabolic bone phenotype. To test this possibility, we used viral vector-mediated overexpression of 
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NPY in Y1−/− mice. Increased hypothalamic NPY, while capable of reducing osteoblast activity in both 
wildtype and Y1 receptor knockout mice, did not abolish the greater osteoblast activity of the Y1−/− 
model. Thus, it seems that other signals-possibly through androgens-and not solely changes in central 
NPY-ergic activity are critical to the anabolic activity associated with Y1−/− mice. 
 Appreciation of the skeletal effects of leptin has increased the need for greater understanding 
of the regulation of adipose tissue and its relationship to bone homeostasis. Y1 signaling, in addition to 
its effects in bone, also regulates adipose tissue, with increased fat mass in both sexes of Y1−/− 
mice.22 As in bone, this activity was not induced by deletion of hypothalamic Y1 receptors, suggesting 
local regulation.3 The findings of reduced body weight in Y1−/−;ob/ob mice relative to ob/ob mice are in 
accordance with previous reports for Y115 and other Y receptors.17,23 However, there were sex-specific 
differences in the influence of Y1 signaling on fat, suggesting modulation of Y1 actions by endocrine 
factors. In females, deletion of Y1 receptors increased WAT mass in normal mice, as well as 
accentuated fat accrual in the hypogonadal and leptin-deficient ob/ob models. Of note, the significantly 
greater fat mass but reduced body weight of female Y1−/−;ob/ob compared with ob/ob mice showed 
that the weight reduction to be through loss of lean mass. This is most likely because of change in 
organ weight, such as liver and intestine rather than muscle mass, because IGF-1 levels in female 
Y1−/−;ob/ob are not reduced relative to wildtype values as are female ob/ob levels. 
 In contrast to females, Y1 receptor deficiency in male ob/ob mice resulted in significant 
reductions in body weight and adiposity. It is noteworthy that the significant hyperinsulinemia of ob/ob 
mice was attenuated in male but not female Y1−/−;ob/ob mice. Because insulin is lipogenic and 
promotes partitioning of fuels toward WAT and away from muscle24,25 the reduction in serum insulin 
levels seen in male Y1−/−;ob/ob mice may have contributed to their associated reduction in adiposity. 
The net effect of germline Y1 receptor knockout on serum insulin levels is likely a balance between 
effects of Y1 deficiency in the hypothalamus versus Y1 deficiency on the pancreas. In the 
hypothalamus, NPY stimulates insulin secretion, possibly through actions on Y1 and Y5 receptors in 
the ventromedial hypothalamus.26 In the pancreas in contrast, NPY inhibits insulin secretion,27 possibly 
through direct action on Y1 receptors expressed on β cells.28 Therefore, germline lack of Y1 receptors 
may be expected to promote low serum insulin levels (as seen in male Y1−/−;ob/ob mice) through 
actions in the brain but to promote high serum insulin levels (as seen in male and female Y1−/− and 
female Y1−/−;ob/ob mice) through actions in pancreatic tissue. It is not clear why central effects of Y1 
receptor deficiency seem to predominate over peripheral (pancreatic) effects of Y1 receptor deficiency 
on serum insulin in male ob/ob mice, but this difference may be related to differential effects of male 
and female gonadal steroids on the hypothalamus.29,30 
 With the exception of male ob/ob mice in which fat mass was reduced by Y1 deletion as 
discussed above, Y1 receptor deletion significantly increased body weight and/or adiposity in every 
other experimental model under study (male and female Y1−/− mice, male and female 
gonadectomized mice, female ob/ob mice, and female mice with hypothalamic overexpression of 
NPY). Interestingly, although androgens seem to be permissive for the effects of Y1 deficiency to 
promote bone anabolic effects, there is no such permissive role of androgens for the Y1-mediated 
regulation of fat mass, because orchidectomized male mice also exhibit increased adiposity. The 
adipogenic effects of Y1 deficiency are likely related to increased circulating insulin levels seen in Y1 
receptor knockout models from this and other laboratories.29,30-33 
 Interestingly, the adipogenic effects of Y1 receptor deficiency were strong enough to overcome 
the weight loss and fat loss induced by orchidectomy in male mice. Estrogen deficiency increases fat 
mass and is evident after menopause or after surgical ovariectomy.34,35 Central NPY levels have been 
implicated in both of these processes,36-38 with hypothalamic NPY expression being elevated after 
ovariectomy29,30 but is reduced by estradiol administration.39 In contrast, central NPY-ergic expression 
is increased by testosterone and reduced by orchidectomy.40 Consistent with this relationship, fat mass 
was increased by ovariectomy and reduced by orchidectomy in wildtype mice. However, this effect of 
orchidectomy to reduce body weight and fat mass was abolished in Y1−/− mice, orchidectomized Y1 
deficient mice being significantly fatter than sham-operated knockouts. 
 The understanding of the influence of adipocytes on bone mass has recently been expanded, 
with identification of marrow adiposity as a risk factor for fracture.41 Leptin20,42 and sex steroids43 are 
known regulators of marrow adiposity, through control of apoptosis. Consistently, in this study, leptin-
deficient and gonadectomized mice displayed increased marrow adiposity in both male and female 
mice, through marked increases in marrow adipocyte number. Moreover, Y1 deficiency altered these 
process, reducing in marrow adiposity in male and female Y1−/−;ob/ob mice but increasing marrow 
adiposity in gonadectomized Y1−/− mice relative to wildtype mice. Whereas this presents a relatively 
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simple picture, the regulation of marrow adipose is complex. For example, leptin deficiency increases 
long bone adiposity but does not alter axial sites.20 The increase in marrow adiposity in ob/ob mice can 
be reversed with peripheral44 or central42,45 leptin treatment, indicating multiple regulatory sites. 
Similarly, sex hormone deficiency, increased long bone adiposity in the metaphyseal but not 
epiphyseal region, through varied responses to β3 adrenergic signaling.46 Interestingly, hypothalamic 
NPY overexpression did not alter marrow adiposity, despite marked increases in peripheral fat 
accrual,12 indicating specific regulatory axes to marrow versus other fat stores. The regulation of 
marrow adiposity therefore seems to be different, at least in part, from that of other adipose stores. 
Given the presence of a number of adipokine receptors on bone cells, these differences in marrow 
adipocyte regulation and therefore local signaling in the bone microenvironment may have important 
consequences for bone mass. 
        The genetic, surgical, and pharmacological techniques used in this study have enabled a more 
defined view of the key role for Y1 receptors in the control of both bone and adipose homeostasis. The 
studies described here indicate a requirement for androgens in the activation of the bone anabolic 
response to lack of Y1 signaling. This finding is of particular importance, given that an age-related 
decline of androgen levels is associated with a gradual decline in bone mass in males.47 These studies 
also support an important role for Y1 receptors in the control of adipose deposition in a variety of 
circumstances (leptin deficiency, gonadal steroid deficiency, and hypothalamic overexpression of 
NPY). Moreover, these studies have shown for the first time the ability of Y1 receptor deletion to modify 
adipose production within the bone microenvironment. This study thereby showed the diverse modes 
of action of Y1 receptor signaling in the control of bone and adipose homeostasis opening up potential 
new ways to control these processes.  
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